Azienda Ospedaliera per l'emergenza Cannizzaro
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Scandurra, Giuseppe
NCT04460807 / 2018-000693-30: Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer

Terminated
3
23
Europe
Exemestane, Mestane, Placebo oral tablet
Ente Ospedaliero Ospedali Galliera, Istituto Di Ricerche Farmacologiche Mario Negri, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Federation of Italian Cooperative Oncology Groups
Ovarian Cancer
04/23
04/23
Colaci, Michele
AIDA, NCT05200715: AutoInflammatory Disease Alliance Registry

Recruiting
N/A
3500
Europe, US, RoW
No intervention is foreseen by the protocol.
University of Siena
Hereditary Autoinflammatory Diseases, Schnitzler Syndrome, Behcet Syndrome, PFAPA Syndrome, Still Disease, Autoinflammatory Syndrome, Unspecified, Uveitis, Scleritis, Vexas Syndrome
08/23
08/30
Scandurra, Giuseppa
AxIn, NCT05817903 / 2022-001150-35: Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients

Recruiting
2
118
Europe
Axitinib, Inlyta, Nivolumab
Consorzio Oncotech, Pfizer
Metastatic Renal Cell Carcinoma
04/26
04/27
NCT06235268: Prospective and Multicenter Italian Registry of Locally Advanced-Metastatic Urothelial Carcinoma

Recruiting
N/A
1000
Europe
Active systemic or non-systemic treatment (palliative or observation procedure)
Federation of Italian Cooperative Oncology Groups
Carcinoma, Urothelial
11/25
11/25
BeLIVE, NCT06836219: Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Matched Therapies in a Real-world Scenario

Recruiting
N/A
300
Europe
Consorzio Oncotech
Ovarian Cancer
01/29
01/29
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Scandurra, Giuseppe
NCT04460807 / 2018-000693-30: Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer

Terminated
3
23
Europe
Exemestane, Mestane, Placebo oral tablet
Ente Ospedaliero Ospedali Galliera, Istituto Di Ricerche Farmacologiche Mario Negri, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Federation of Italian Cooperative Oncology Groups
Ovarian Cancer
04/23
04/23
Colaci, Michele
AIDA, NCT05200715: AutoInflammatory Disease Alliance Registry

Recruiting
N/A
3500
Europe, US, RoW
No intervention is foreseen by the protocol.
University of Siena
Hereditary Autoinflammatory Diseases, Schnitzler Syndrome, Behcet Syndrome, PFAPA Syndrome, Still Disease, Autoinflammatory Syndrome, Unspecified, Uveitis, Scleritis, Vexas Syndrome
08/23
08/30
Scandurra, Giuseppa
AxIn, NCT05817903 / 2022-001150-35: Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients

Recruiting
2
118
Europe
Axitinib, Inlyta, Nivolumab
Consorzio Oncotech, Pfizer
Metastatic Renal Cell Carcinoma
04/26
04/27
NCT06235268: Prospective and Multicenter Italian Registry of Locally Advanced-Metastatic Urothelial Carcinoma

Recruiting
N/A
1000
Europe
Active systemic or non-systemic treatment (palliative or observation procedure)
Federation of Italian Cooperative Oncology Groups
Carcinoma, Urothelial
11/25
11/25
BeLIVE, NCT06836219: Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Matched Therapies in a Real-world Scenario

Recruiting
N/A
300
Europe
Consorzio Oncotech
Ovarian Cancer
01/29
01/29

Download Options